Search Results - "Isacoff, William H"

In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor by VAN DER HEIJDEN, Michiel S, BRODY, Jonathan R, KERN, Scott E, DEZENTJE, David A, GALLMEIER, Eike, CUNNINGHAM, Steven C, SWARTZ, Michael J, DEMARZO, Angelo M, OFFERHAUS, G. Johan A, ISACOFF, William H, HRUBAN, Ralph H

“…Purpose: BRCA2, FANCC , and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to…”
Get full text

Phase II Trial of Infusional Fluorouracil, Leucovorin, Mitomycin, and Dipyridamole in Locally Advanced Unresectable Pancreatic Adenocarcinoma: SWOG S9700 by ISACOFF, William H, BENDETTI, Jacqueline K, BARSTIS, John J, JAZIEH, Abdul-Rahman, MACDONALD, John S, PHILIP, Philip A

“…To test the hypothesis that dual biochemical modulation of fluorouracil (FU) in combination with mitomycin improves the survival of patients with pancreas…”
Get full text

ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer by Isacoff, William H., Cooper, Brandon, Bartlett, Andrew, McCarthy, Brian, Yu, Kenneth H.

“…Cytotoxic chemotherapy remains the mainstay of treatment for advanced pancreatic adenocarcinoma (PDAC). Emerging studies support metronomic chemotherapy (MCT)…”
Get full text

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis by Isacoff, William H., Reber, Howard A., Bedford, Rudolph, Hoos, William, Rahib, Lola, Upfill-Brown, Alexander, Donahue, Timothy, Hines, O. Joe

“…Background Continuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab- paclitaxel and oxaliplatin have been shown to be active in patients with…”
Get full text

Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival by Kadera, Brian E, Sunjaya, Dharma B, Isacoff, William H, Li, Luyi, Hines, O Joe, Tomlinson, James S, Dawson, David W, Rochefort, Matthew M, Donald, Graham W, Clerkin, Barbara M, Reber, Howard A, Donahue, Timothy R

“…Treatment of patients with locally advanced/borderline resectable (LA/BR) pancreatic ductal adenocarcinoma (PDAC) is not standardized. To (1) perform a…”
Get more information

Impact of Splenectomy on Thrombocytopenia, Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer by Donahue, Timothy R., Kazanjian, Kevork K., Isacoff, William H., Reber, Howard A., Hines, O. Joe

“…Background Patients with unresectable pancreatic cancer (PDAC) or endocrine tumors (PET) often develop splenic vein thrombosis, hypersplenism, and…”
Get full text

Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy by Beseth, B D, Bedford, R, Isacoff, W H, Holmes, E C, Cameron, R B

“…The accuracy of endoscopic ultrasound (EUS) for initial staging of esophageal cancer is widely accepted. There is, however, considerable variability in the…”
Get more information

Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy by Büchler, Peter, Reber, Howard A, Eibl, Guido, Roth, Mendel A, Büchler, Markus W, Friess, Helmut, Isacoff, William H, Hines, Oscar J

“…The HER2/neu oncogene is overexpressed in up to 70% of human pancreatic cancer specimens when compared to normal pancreatic tissue. This cell surface receptor…”
Get more information

Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery by Donahue, Timothy R, Isacoff, William H, Hines, O Joe, Tomlinson, James S, Farrell, James J, Bhat, Yasser M, Garon, Edward, Clerkin, Barbara, Reber, Howard A

“…To determine whether computed tomography (CT)/magnetic resonance imaging (MRI) signs of vascular involvement are accurate after downstaging chemotherapy (DCTx)…”
Get more information

Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin) by Büchler, Peter, Reber, Howard A., Büchler, Manuela C., Roth, Mendel A., Büchler, Markus W., Friess, Helmut, Isacoff, William H., Hines, Oscar J.

“…The HER2/neu oncogene is overexpressed in human pancreatic cancer, but the clinical significance of that overexpression is uncertain. In the present study we…”
Get full text

Chemotherapy for the Treatment of Patients with Metastatic Colorectal Cancer: An Overview by Isacoff, William H., Borud, Katrina

“…Approximately 50% of patients with colorectal cancer develop locally recurrent or distant metastatic disease during the course of their illness and eventually…”
Get full text

Abstract 5183: Retrospective analysis of CCNG1 expression in tumors, a novel biomarker in development for partnering with DRG-101, a tumor targeted retrovector encoding a CCNG1 inhibitor gene by Omelchenko, Nadezhda, Kumar, Vaishali, Jeffrey, Samantha, Haroun, Grace, Brigham, Don, Isacoff, William H., Chawla, Sant

“…Abstract Background: CCNG1, a non-canonical cyclin, is a novel biomarker in development for partnering with DRG-101 (DeltaRex-G), a tumor targeted retrovector…”
Get full text

Pharmacogenomic blood-based assay to predict chemotherapy response and survival in pancreatic cancer by Yu, Kenneth H., McCarthy, Brian, Isacoff, William H., Cooper, Brandon, Bartlett, Andrew, Park, Jennifer, Purcell, Fay, McCarthy, Devan, O'Reilly, Eileen Mary

“…Abstract only 738 Background: Pancreatic adenocarcinoma (PDAC) is for most patients a refractory disease. Modern cytotoxic chemotherapeutics (C) are not yet…”
Get full text

Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections by Duffy, John P, Hines, Oscar J, Liu, Jerome H, Ko, Clifford Y, Cortina, Galen, Isacoff, William H, Nguyen, Henry, Leonardi, Michael, Tompkins, Ronald K, Reber, Howard A

“…After resection of an adenocarcinoma of the ampulla of Vater, certain clinical and pathologic characteristics influence long-term survival. Retrospective case…”
Get more information

Evaluation of a cell viability assay based on cultures of CTICs to identify treatment options in third-line pancreatic cancer by Ricigliano, Mark, Isacoff, William H., Ocean, Allyson J., Cooper, Brandon, Welkie, Mary, Bartlett, Andrew, Yu, Kenneth H.

“…Abstract only 338 Background: Standard of care treatment for pancreatic adenocarcinoma (PDAC) includes FOLFIRINOX or gemcitabine with nab-paclitaxel used in…”
Get full text

In Reply by Isacoff, William H., Philip, Philip A.

Get full text

Pancreatic circulating tumor cells as a diagnostic adjunct in pancreatic cancer by Ankeny, Jacob S, Hou, Shuang, Lin, Millicent, OuYang, Hank, Song, Min, Rochefort, Matthew M, Girgis, Mark D, Isacoff, William H., Wainberg, Zev A., Tseng, Hsian-Rong, Tomlinson, James S

“…Abstract only 175 Background: Current diagnosis of pancreatic ductal adenocarcinoma (PDAC) relies upon image guided tissue sampling, which is expensive,…”
Get full text

Metronomic therapy with 5-FU, weekly nab-paclitaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: A phase II study by Isacoff, William H., Reber, Howard A., Hines, Oscar J, Donahue, Timothy R., Purcell, Fay M., Clerkin, Barbara M., Clerkin, Kara M.

“…Abstract only e14582 Background: The objective of this open label phase 2 study was to evaluate low-dose continuous (metronomic) chemotherapy given in…”
Get full text

Clinical management of long-term cancer survivors by Isacoff, William H, Philip, Philip A

Get full text

Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole by Todd, Karen E., Gloor, Beat, Lane, John S., Isacoff, William H., Reber, Howard A.

“…Patients with locally advanced pancreatic adenocarcinoma who receive conventional therapy with radiation with 5-fluorouracil (5-FU) have median survivals…”
Get full text